New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
13:12 EDTIBM, GOOG, CREE, AMD, ISRG, COH, DGX, MAPP, AGNOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday as the Dow was lifted by an advance in IBM (IBM) shares and the Nasdaq was similarly boosted by Google's (GOOG) outperformance. The S&P has been a laggard all morning, remaining near the flat line since the open, but is back in positive ground in afternoon trading... ECONOMIC EVENTS: In the U.S., the light economic calendar included the Home Price Index, which showed prices rose 0.6% in November, versus expectations for an increase of 0.7%. Also of note, the International Monetary Fund lowered its outlook for 2013 global output growth to 3.5% from 3.6%... COMPANY NEWS: IBM advanced over 5% at midday after its earnings report and guidance exceeded expectations. Google similarly reported earnings that beat consensus and price targets on its shares were raised all over The Street. Google advanced over 6% following the report... Among others reporting earnings last night and this morning, advancers included Cree (CREE), Advanced Micro Devices (AMD) and Intuitive Surgical (ISRG); decliners included Coach (COH) and Quest Diagnostics (DGX)... MAJOR MOVERS: Among the notable gainers not moving on earnings was MAP Pharmaceuticals (MAPP), which rose 58.6% to $24.71 after agreeing to be acquired by Allergan (AGN) for $25 per share. Allergan shares fell 1.2% following the announcement. Also lower were shares of Molycorp (MCP), which fell about 9% after disclosing it now sees Q4 and 1H13 production substantially lower than expected... INDICES: Near 1 pm ET, the Dow was up 67.87, or 0.49%, to 13,780.08; the Nasdaq was up 9.63, or 0.31%, to 3,152.81; and the S&P 500 was up 0.74, or 0.05%, to 1,493.30.
News For IBM;GOOG;CREE;AMD;ISRG;COH;DGX;MAPP;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
October 9, 2014
14:00 EDTAMDTiming of AMD CEO changes suggest another disappointing quarter, says Argus
After AMD announced last night that its CEO has stepped down, Argus notes that the change in the role is the fourth at the company since 2008 and that its suddenness suggests that its just ended quarter, which will be reported on in a week, will be disappointing. The firm believes executive turnover adds to the view that AMDís business model is flawed or broken and Argus maintains its Hold rating on the stock.
12:28 EDTAGNAllergan price target raised to $230 from $210 at BTIG
BTIG said it expected Allergan to beat the consensus forecast for Q3 EPS, but not by as much as it did, and the firm did not expect the company to raise its future EPS outlook yet again. BTIG feels the stock's move higher indicates Valeant (VRX) or Actavis (ACT) would need to bid above $200 if they hope to buy the company. BTIG maintains its Buy rating on Allergan and raised its price target on the stock to $230 from $210.
11:14 EDTAGNAllergan raises outlook again as Valeant pursuit continues
Drug maker Allergan (AGN) this morning preannounced stronger than expected results and again raised its fiscal year profit guidance. The beat and raise results come after The Wall Street Journal reported on Tuesday that drug maker Valeant (VRX) and hedge fund Pershing Square intend to raise their previous bid for Allergan by $15 per share to about $191. Meanwhile, also on Tuesday, Reuters said that drug maker Actavis (ACT) plans to make a new merger offer to Allergan, and sources indicated to the news service that Allergan may be willing to consider an offer from Actavis if the bid is for more than $200 per share. WHAT'S NEW: Allergan estimated that its third quarter earnings per share would come in at $1.76-$1.78, versus analysts' consensus estimate of $1.48. The drug maker had previously provided Q3 EPS guidance of $1.44-$1.47. Allergan raised its fiscal 2014 EPS guidance to $6.20-$6.25 from $5.74-$5.80. Analysts' consensus estimate was $5.81. This is the fourth time that Allergan has raised its guidance this year. Allergan said that its markets have been strong around the world, while it is gaining market share in most categories. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that, in the wake of Allergan's guidance increase, the company's price to earnings multiple could expand to 22x its estimated 2016 earnings, up from its current multiple of 19x. In addition to the raised guidance, a potential accretive acquisition by Allergan and the possibility that it will be acquired make such an increase in the multiple "quite possible," Biegelsen contended. He kept an Outperform rating on the stock. WHAT'S NOTABLE: Allergan has reportedly held advanced talks about acquiring another company in the sector, Salix (SLXP), although CNBC's David Faber on October 2 reported that the talks between the two companies about a merger had "cooled considerably." PRICE ACTION: In late morning trading, Allergan rose fractionally to $191.06 while Valeant slid 1.5% to $124.08.
10:06 EDTCREECree calls active on renewed takeover chatter
Subscribe for More Information
10:00 EDTAGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTAMDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:42 EDTCREERumor: Cree moves up on renewed takeover chatter
Subscribe for More Information
09:41 EDTCOHBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
09:20 EDTAMDOn The Fly: Pre-market Movers
Subscribe for More Information
08:50 EDTAGNAllergan shares have further upside, says Wells Fargo
Subscribe for More Information
08:08 EDTAMDAMD downgraded at Wedbush
Subscribe for More Information
07:11 EDTAMDAMD downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
06:49 EDTAGNAllergan cites momentum from robust growth of worldwide markets
The company also cites increases in market share in most categories, many regulatory approvals for new products in the U.S. and internationally, and targeted investments to create and grow new products and new categories. Exceptional growth in EPS from the acceleration in sales but also in leveraging of sales and marketing expenditures. The benefits from Allerganís previously announced restructuring program will be reflected in the Companyís actual results beginning in the fourth quarter of 2014 and continuing through 2015.
06:47 EDTAGNAllergan sees FY16 non-GAAP EPS $10.25
06:47 EDTAGNAllergan sees FY15 non-GAAP EPS $8.60, consensus $8.25
Subscribe for More Information
06:47 EDTAGNAllergan sees FY14 non-GAAP EPS $6.20-$6.25, consensus $5.81
Subscribe for More Information
06:46 EDTAGNAllergan raises Q3 EPS to $1.76-$1.78 from $1.44-$1.47, consensus $1.48
Expects Q3 product net sales to increase in excess of 17% in dollars compared to product net sales from 3Q13.
06:34 EDTCREEGlobal LED lighting demand to grow 180%-190% by 2018, DigiTimes Research says
Subscribe for More Information
06:29 EDTGOOGIDC: Worldwide PC shipments down 1.7% in Q3, DigiTimes reports
Worldwide PC shipments are down 1.7% with 78.5M units shipped in Q3, reports DigiTimes, citing the IDC. Shipments in the US grew 4.3% to 17.3M, with growth centered from strong momentum in te portables category. Reference Link
06:26 EDTGOOGGoogle's tax arrangement facing new challenge by France, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use